A trial of mesenchymal stem cell is planned for the end of 2010.
Preclinical work supports the use of mesenchymal stem cells to treat neurodegenerative disorders.
A new BDNF inducer enters the pipeline.
The search for genetic modifiers is an important part of the effort to find treatments.
Overexpression of the RCAN1 gene may be a treatment for Huntington's Disease.
Researchers have identified the mechanism by which axonal transport is impaired in neurons in HD.
Researchers at Johns Hopkins have discovered that a protein called rhes binds to the HD protein and causes toxicity
MSG-MIND researchers discover a new therapeutic target: increased acetylation enhances clearance of the HD ptotein from the nucleus.
Clear differences were found among the control group, premanifest gene carriers, and those in early stages.
This article describes other possible diagnoses when there are clinical signs of HD but a negative gene test.
